S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
Log in

NYSE:ZTS - Zoetis Stock Price, Forecast & News

$116.03
+4.11 (+3.67 %)
(As of 04/2/2020 04:00 PM ET)
Today's Range
$110.87
Now: $116.03
$116.30
50-Day Range
$92.66
MA: $127.82
$144.94
52-Week Range
$90.14
Now: $116.03
$146.26
Volume2.40 million shs
Average Volume2.75 million shs
Market Capitalization$55.11 billion
P/E Ratio37.19
Dividend Yield0.71%
Beta0.79
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices and genetics. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More
Zoetis logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.26 billion
Cash Flow$4.49 per share
Book Value$5.69 per share

Profitability

Net Income$1.50 billion

Miscellaneous

Employees10,600
Market Cap$55.11 billion
Next Earnings Date5/6/2020 (Confirmed)
OptionableOptionable

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.


Zoetis (NYSE:ZTS) Frequently Asked Questions

How has Zoetis' stock been impacted by COVID-19 (Coronavirus)?

Zoetis' stock was trading at $130.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZTS stock has decreased by 10.9% and is now trading at $116.03. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zoetis?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zoetis.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Zoetis.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Wednesday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) announced its quarterly earnings results on Thursday, February, 13th. The company reported $0.92 EPS for the quarter, topping the Zacks' consensus estimate of $0.88 by $0.04. The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.64 billion. Zoetis had a net margin of 23.96% and a return on equity of 69.41%. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period last year, the firm earned $0.79 EPS. View Zoetis' earnings history.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Tuesday, February 11th. Investors of record on Friday, April 17th will be paid a dividend of $0.20 per share on Monday, June 1st. This represents a $0.80 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Thursday, April 16th. View Zoetis' dividend history.

How will Zoetis' stock buyback program work?

Zoetis announced that its Board of Directors has authorized a share buyback plan on Wednesday, December 12th 2018, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 4.7% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its stock is undervalued.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share (EPS) guidance of $3.90-4.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.01. The company issued revenue guidance of $6.65-6.80 billion, compared to the consensus revenue estimate of $6.69 billion.

What price target have analysts set for ZTS?

17 brokers have issued 12 month price targets for Zoetis' stock. Their forecasts range from $105.00 to $162.00. On average, they expect Zoetis' share price to reach $135.40 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price. View analysts' price targets for Zoetis.

Has Zoetis been receiving favorable news coverage?

Media stories about ZTS stock have trended very negative on Thursday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zoetis earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutZoetis.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 5,247,200 shares, an increase of 17.9% from the February 27th total of 4,450,000 shares. Based on an average trading volume of 2,090,000 shares, the days-to-cover ratio is currently 2.5 days. Approximately 1.1% of the shares of the stock are short sold. View Zoetis' Current Options Chain.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Who are Zoetis' key executives?

Zoetis' management team includes the following people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Neville Rodie & Shaw Inc. (0.03%), Park National Corp OH (0.03%), Bath Savings Trust Co (0.00%), Fulcrum Equity Management (0.00%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View institutional ownership trends for Zoetis.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, and Neville Rodie & Shaw Inc.. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano, and Willie M Reed. View insider buying and selling activity for Zoetis.

Which major investors are buying Zoetis stock?

ZTS stock was purchased by a variety of institutional investors in the last quarter, including Fulcrum Equity Management, Bath Savings Trust Co, and Nelson Van Denburg & Campbell Wealth Management Group LLC. View insider buying and selling activity for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $116.03.

How big of a company is Zoetis?

Zoetis has a market capitalization of $55.11 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis. Zoetis employs 10,600 workers across the globe. View additional information about Zoetis.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com/.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  822 (Vote Outperform)
Underperform Votes:  472 (Vote Underperform)
Total Votes:  1,294
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel